MicroPort CardioFlow Revises Transaction Cap

MicroPort CardioFlow Medtech Corp. (HK:2160) has released an update.

MicroPort CardioFlow Medtech Corporation has provided guarantees for MP CardioAdvent’s repayment obligations under Facility Agreements and revised the annual cap for connected transactions under the 2023 Master Service Procurement Agreement. The company is a controlling shareholder of MP CardioAdvent and these transactions are subject to reporting and annual review as per Listing Rules. The revisions are exempt from requiring a circular or independent shareholder approval as the applicable percentage ratios for the transactions are between 0.1% and 5%.

For further insights into HK:2160 stock, check out TipRanks’ Stock Analysis page.